ABSTRACT Middle East respiratory syndrome coronavirus (MERS-CoV) causes a highly lethal respiratory infection for which no vaccines or antiviral therapeutics are currently available . Understanding the immune response is critical for designing effective therapeutics . Here, we comprehensively characterized the dynamics of B-cell responses in severely infected MERS-CoV patients and survivors with SARS-CoV-2 exposure history . Infected patients developed robust neutralizing antibody responses within 1 month of illness , with moderate-to-high cross-neutralization activity against SARS-CoV-2 . The enhanced neutralization activity coincided with an increased abundance of specific mutated, class-switched IgG clones. Notably, one such clone was detected at moderate prevalence in both patients, and its expansion was accompanied by high neutralization activity against both viruses . Conversely, MERS-CoV survivors demonstrated higher neutralization activity against MERS-CoV after vaccinati...
Media Monitoring for Signals about Emerging Threats